{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T10:35:45Z","timestamp":1767177345116,"version":"build-2238731810"},"reference-count":31,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2015,3,12]],"date-time":"2015-03-12T00:00:00Z","timestamp":1426118400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0119897","type":"journal-article","created":{"date-parts":[[2015,3,12]],"date-time":"2015-03-12T13:51:03Z","timestamp":1426168263000},"page":"e0119897","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":15,"title":["Adverse Events of Anti-Tumor Necrosis Factor \u03b1 Therapy in Ankylosing Spondylitis"],"prefix":"10.1371","volume":"10","author":[{"given":"Qiang","family":"Tong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tristan","family":"de Mooij","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xia","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shengming","family":"Dai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenchun","family":"Qu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongbao","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2015,3,12]]},"reference":[{"key":"ref1","first-page":"281","article-title":"The United States National Health and Nutrition Examination Survey and the Epidemiology of Ankylosing Spondylitis in the United States: Am J Med Sci","volume":"341","author":"CF Dillon","year":"2011","journal-title":"The United States National Health and Nutrition Examination Survey and the Epidemiology of Ankylosing Spondylitis in the United States: Am J Med Sci"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"479","DOI":"10.3899\/jrheum.100686","article-title":"Work disability in patients with ankylosing spondylitis in Norway","volume":"38","author":"G Bakland","year":"2011","journal-title":"J Rheumatol"},{"issue":"4","key":"ref3","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.jbspin.2014.01.003","article-title":"Should non-steroidal anti-inflammatory drugs be used continuously in ankylosing spondylitis?","volume":"81","author":"D Guellec","year":"2014","journal-title":"Joint Bone Spine"},{"issue":"9906","key":"ref4","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1016\/S0140-6736(13)61134-4","article-title":"Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial","volume":"382","author":"D Baeten","year":"2013","journal-title":"Lancet"},{"issue":"Suppl 1","key":"ref5","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1186\/1478-6354-13-S1-S4","article-title":"Structural damage in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: traditional views, novel insights gained from TNF blockade, and concepts for the future","volume":"13","author":"G Schett","year":"2011","journal-title":"Arthritis Res Ther"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1002\/art.30223","article-title":"Clinical efficacy and safety of Etanercept versus sulfasalazine in ankylosing spondylitis patients: A randomized, double-blind study (ASCEND Trial)","volume":"63","author":"J Braun","year":"2011","journal-title":"Arthritis Rheum"},{"key":"ref7","article-title":"Efficacy of TNF\u03b1 blockers in patients with ankylosing spondylitis and non-radiographic axials pondyloarthritis: a meta-analysis","volume":"9","author":"J Callhoff","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.2217\/pgs.12.133","article-title":"TNF-\u03b1-857 and-1031 polymorphisms predict good therapeutic response to TNF-\u03b1 blockers in Chinese Han patients with ankylosing spondylitis","volume":"13","author":"Q Tong","year":"2012","journal-title":"Pharmacogenomics"},{"issue":"11","key":"ref9","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1136\/ard.2008.092833","article-title":"Formation of antibodies against infliximab and adalimumab strongly correlates with functionaldrug levels and clinical responses in rheumatoid arthritis","volume":"68","author":"TR Radstake","year":"2009","journal-title":"AnnRheum Dis"},{"issue":"4","key":"ref10","doi-asserted-by":"crossref","first-page":"R131","DOI":"10.1186\/ar2020","article-title":"Predictors of infusion reactions during infliximab treatment in patients with arthritis","volume":"8","author":"MC Kapetanovic","year":"2006","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"ref11","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/j.1398-9995.2009.02280.x","article-title":"Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions","volume":"65","author":"A Vultaggio","year":"2010","journal-title":"Allergy"},{"key":"ref12","author":"A Eudy"},{"issue":"4","key":"ref13","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/art.1780270401","article-title":"Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria","volume":"27","author":"S van der Linden","year":"1984","journal-title":"Arthritis Rheum"},{"key":"ref14","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 published May 28 2009. National Cancer Institute, U.S. National Institutes of Health."},{"issue":"14","key":"ref15","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.2217\/pgs.13.146","article-title":"Association of TNF-\u03b1 polymorphism with prediction of response to TNF blockers in spondyloarthritis and inflammatory bowel disease: a meta-analysis","volume":"14","author":"Q Tong","year":"2013","journal-title":"Pharmacogenomics"},{"key":"ref16","article-title":"Efficacy of TNF\u03b1 blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis","volume":"9","author":"J Callhoff","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"ref17","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1556\/OH.2011.28987","article-title":"Adverse events during biological therapy-focusing on dermatological side-effects","volume":"152","author":"G Nagy","year":"2011","journal-title":"Orv Hetil"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1007\/s00415-010-5591-7","article-title":"Neurological adverse events associated with anti-tumor necrosis factor alpha treatment","volume":"257","author":"AG Tristano","year":"2010","journal-title":"J Neurol"},{"key":"ref19","first-page":"238","article-title":"Sustained efficacy and safety, including patient-reported outcomes, with Etanercept treatment over 5 years in patients with ankylosing spondylitis","volume":"28","author":"E Mart\u00edn-Mola","year":"2010","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"ref20","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/j.1365-2133.2007.07682.x","article-title":"Cutaneous side-effects in patients with rheumatic diseases during application of tumour necrosis factor-alpha antagonists","volume":"156","author":"HH Lee","year":"2007","journal-title":"Br J Dermatol"},{"issue":"8","key":"ref21","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1007\/s12325-012-0037-5","article-title":"Treatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settings","volume":"29","author":"M Bonafede","year":"2012","journal-title":"Adv Ther"},{"issue":"2","key":"ref22","first-page":"122","article-title":"A short-term efficacy and safety study of infliximab in active ankylosing spondylitis","volume":"45","author":"F Huang","year":"2006","journal-title":"Zhonghua Nei Ke Za Zhi"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1093\/rheumatology\/kep083","article-title":"Paradoxical adverse events of anti-tumour necrosis factor therapy for spondyloarthropathies: a retrospective study","volume":"48","author":"D Fouache","year":"2009","journal-title":"Rheumatology (Oxford)"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1136\/ard.2007.069484","article-title":"Focus on adverse events of tumour necrosis factor alpha blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients","volume":"67","author":"V Gerloni","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1590\/S0482-50042010000200006","article-title":"Immediate complications of 3,555 injections of anti-TNF\u03b1","volume":"50","author":"JC de Moraes","year":"2010","journal-title":"Rev Bras Reumatol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1002\/art.21978","article-title":"Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register","volume":"54","author":"WG Dixon","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"2","key":"ref27","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/j.1756-185X.2009.01393.x","article-title":"The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study at the university-based hospital","volume":"12","author":"P Suwannalai","year":"2009","journal-title":"Int J Rheum Dis"},{"issue":"9","key":"ref28","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1136\/ard.62.9.829","article-title":"Systematic safety follow-up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease?","volume":"62","author":"D Baeten","year":"2003","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"ref29","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1586\/1744666X.4.3.379","article-title":"C-reactive protein at the interface between innate immunity and inflammation","volume":"4","author":"A Peisajovich","year":"2008","journal-title":"Expert Rev Clin Immunol"},{"issue":"1","key":"ref30","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/hmg\/ddh021","article-title":"Polymorphism at the C-reactive protein locus influences gene expression and predisposes to systemic lupus erythematosus","volume":"13","author":"AI Russell","year":"2004","journal-title":"Hum Mol Genet"},{"issue":"12","key":"ref31","first-page":"2286","article-title":"A new approach to defining disease status in ankylosing spondylitis: the BathAnkylosing Spondylitis Disease Activity Index","volume":"21","author":"S Garrett","year":"1994","journal-title":"J Rheumatol"}],"updated-by":[{"DOI":"10.1371\/journal.pone.0127488","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2015,4,27]],"date-time":"2015-04-27T00:00:00Z","timestamp":1430092800000}}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0119897","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,30]],"date-time":"2020-08-30T15:55:05Z","timestamp":1598802905000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0119897"}},"subtitle":[],"editor":[{"given":"Antony Nicodemus","family":"Antoniou","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2015,3,12]]},"references-count":31,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2015,3,12]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0119897","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,12]]}}}